Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.

PCSA

Processa Pharmaceuticals (PCSA)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA
DataOraFonteTitoloSimboloCompagnia
07/09/202214:30GlobeNewswire Inc.Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022NASDAQ:PCSAProcessa Pharmaceuticals Inc
07/09/202212:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PCSAProcessa Pharmaceuticals Inc
23/08/202222:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PCSAProcessa Pharmaceuticals Inc
16/08/202214:30GlobeNewswire Inc.Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the BoardNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/08/202213:31TipRanksAnalysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and Processa Pharmaceuticals (PCSA)NASDAQ:PCSAProcessa Pharmaceuticals Inc
12/08/202215:30GlobeNewswire Inc.Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/08/202221:00GlobeNewswire Inc.Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
04/08/202215:30GlobeNewswire Inc.Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499NASDAQ:PCSAProcessa Pharmaceuticals Inc
03/08/202222:00GlobeNewswire Inc.Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499NASDAQ:PCSAProcessa Pharmaceuticals Inc
12/07/202214:30GlobeNewswire Inc.Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022NASDAQ:PCSAProcessa Pharmaceuticals Inc
11/07/202222:44Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PCSAProcessa Pharmaceuticals Inc
31/05/202214:06Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
31/05/202214:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
12/05/202222:20GlobeNewswire Inc.Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/05/202214:30GlobeNewswire Inc.Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
20/04/202214:30GlobeNewswire Inc.Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)NASDAQ:PCSAProcessa Pharmaceuticals Inc
05/04/202214:30GlobeNewswire Inc.Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of GastroparesisNASDAQ:PCSAProcessa Pharmaceuticals Inc
30/03/202222:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PCSAProcessa Pharmaceuticals Inc
30/03/202222:00GlobeNewswire Inc.Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
24/03/202221:16Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PCSAProcessa Pharmaceuticals Inc
23/03/202213:30GlobeNewswire Inc.Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
10/03/202214:30GlobeNewswire Inc.Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
26/01/202214:15GlobeNewswire Inc.Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022NASDAQ:PCSAProcessa Pharmaceuticals Inc
06/01/202223:31Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
12/11/202112:15Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PCSAProcessa Pharmaceuticals Inc
11/11/202122:05GlobeNewswire Inc.Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
04/11/202113:15GlobeNewswire Inc.Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim AnalysisNASDAQ:PCSAProcessa Pharmaceuticals Inc
26/10/202114:30GlobeNewswire Inc.Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
12/10/202114:30GlobeNewswire Inc.Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of GastroparesisNASDAQ:PCSAProcessa Pharmaceuticals Inc
16/09/202117:05GlobeNewswire Inc.Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network